Olema Pharmaceuticals, Inc.
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
OLMA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US68062P1066
- LEI:
- Country:
- United States of America
- Address:
- 780 BRANNAN STREET, 94103 SAN FRANCISCO
- Website:
- https://olema.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Operating as Olema Oncology, the company is dedicated to transforming the standard of care, with a primary focus on breast cancer. Its lead product candidate, palazestrant (OP-1250), is a novel, investigational agent being developed for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Olema's mission is to develop more effective and tolerable medicines to improve patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Olema Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Olema Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Olema Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
